Vaxcyte (PCVX) Stock
Clinical stage biotech developing vaccines for infectious diseases. Here's the price, business snapshot, and what's worth knowing about Vaxcyte in October 2026.
Vaxcyte Inc (PCVX) is a clinical-stage biotechnology company focused on developing next-generation vaccines. The company’s lead programmes include a pneumococcal conjugate vaccine candidate designed to broaden serotype coverage and other vaccine candidates targeting infectious diseases such as Lyme. With a market capitalisation around $5.50B, Vaxcyte’s valuation reflects investor expectations of successful clinical progress and eventual commercialisation. As a clinical-stage firm it currently has limited product revenue and depends on trial outcomes, partnerships and funding to advance its pipeline. Key investor considerations are trial results, regulatory decisions, competitive dynamics in the vaccine market and manufacturing scale-up. Risks are material: clinical setbacks, regulatory delays, manufacturing challenges and dilution from financing can all affect the share price. This summary is educational only — not investment advice — and suitable for investors who understand biotech risk and a long time horizon.
Vaxcyte (PCVX) Stock Forecast
Analyst price target, next 12 months
$99.36
+75.9% vs today's $56.48
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Vaxcyte have a consensus 12-month target of $99.36, above the current price of $56.48.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 5 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Vaxcyte's stock as it has significant potential for price growth.
Financial Health
Vaxcyte Inc. shows strong cash flow and a solid book value, indicating good financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Late-stage pneumococcal play
Vaxcyte’s pneumococcal candidate aims to expand serotype coverage, which could address unmet need — though success depends on clinical and regulatory outcomes.
Platform-driven vaccine pipeline
A proprietary platform supports multiple candidates, offering leverage if one succeeds; early-stage programmes add upside but also add development risk.
Commercial and competitive dynamics
The global vaccine market offers scale if approved, but competition from established vaccine makers and manufacturing challenges can affect commercial prospects.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
